These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32499237)

  • 21. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In support of an early intensive treatment of type 2 diabetes and not necessarily of early polypharmacy.
    Czupryniak L; Szymańska-Garbacz E; Pawłowski M; Saryusz-Wolska M; Loba J
    Diabetes Obes Metab; 2011 May; 13(5):474-5. PubMed ID: 22017762
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study.
    Nitenberg A; Pham I; Antony I; Valensi P; Attali JR; Chemla D
    Atherosclerosis; 2005 Nov; 183(1):113-20. PubMed ID: 16216594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study.
    Yen CL; Wu CY; See LC; Li YJ; Tseng MH; Peng WS; Liu JR; Chen YC; Yen TH; Tian YC; Yang CW; Anderson GF; Yang HY
    Diabetes Care; 2020 Oct; 43(10):e152-e153. PubMed ID: 32801131
    [No Abstract]   [Full Text] [Related]  

  • 25. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 26. Diabetic complications: current challenges and opportunities.
    Nickerson HD; Dutta S
    J Cardiovasc Transl Res; 2012 Aug; 5(4):375-9. PubMed ID: 22752737
    [No Abstract]   [Full Text] [Related]  

  • 27. Biological variation of cardiovascular risk factors in patients with diabetes.
    Dawson AJ; Sathyapalan T; Atkin SL; Kilpatrick ES
    Diabet Med; 2013 Oct; 30(10):1172-80. PubMed ID: 23413821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes Mellitus and Heart Failure.
    Lehrke M; Marx N
    Am J Cardiol; 2017 Jul; 120(1S):S37-S47. PubMed ID: 28606342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.
    Bhushan R; Elkind-Hirsch KE; Bhushan M; Butler WJ; Duncan K; Marrioneaux O
    Diabetes Technol Ther; 2009 Jun; 11(6):353-9. PubMed ID: 19459763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should all diabetic patients be treated with a statin?
    Kamari Y; Bitzur R; Cohen H; Shaish A; Harats D
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S378-83. PubMed ID: 19875585
    [No Abstract]   [Full Text] [Related]  

  • 31. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
    MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
    [No Abstract]   [Full Text] [Related]  

  • 32. Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients With Type 2 Diabetes: A Cohort Study.
    Al-Salameh A; Bucher S; Bauduceau B; Benattar-Zibi L; Berrut G; Bertin P; Corruble E; Danchin N; Derumeaux G; Doucet J; Falissard B; Forette F; Hanon O; Ourabah R; Pasquier F; Pinget M; Ringa V; Becquemont L
    Can J Diabetes; 2018 Aug; 42(4):365-371.e2. PubMed ID: 29037572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 34. Diabetes Mellitus and Heart Failure.
    Lehrke M; Marx N
    Am J Med; 2017 Jun; 130(6S):S40-S50. PubMed ID: 28526183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning.
    Reaven G
    Circulation; 2005 Nov; 112(20):3030-2. PubMed ID: 16286599
    [No Abstract]   [Full Text] [Related]  

  • 36. [Recent trends in diabetic complications in Japan].
    Sone H; Saito Y; Yoshimura Y; Ishibashi S; Ito H; Yamashita H; Yamazaki Y; Katayama S; Ohashi Y; Akanuma Y; Yamada N
    Nihon Naika Gakkai Zasshi; 2004 Nov; 93(11):2427-34. PubMed ID: 15624483
    [No Abstract]   [Full Text] [Related]  

  • 37. Do not forget that type 2 diabetes does not only expose to cardiovascular complications.
    Halimi S
    Diabetes Metab; 2014 Jun; 40(3):167-8. PubMed ID: 24751987
    [No Abstract]   [Full Text] [Related]  

  • 38. The Diabetes Prevention Program.
    Muniyappa R; El-Atat F; Aneja A; McFarlane SI
    Curr Diab Rep; 2003 Jun; 3(3):221-2. PubMed ID: 12762969
    [No Abstract]   [Full Text] [Related]  

  • 39. [Update diabetes mellitus and cardiovascular diseases].
    Otter W
    MMW Fortschr Med; 2012 Apr; 154(7):95-8. PubMed ID: 22558884
    [No Abstract]   [Full Text] [Related]  

  • 40. Present recommendations in type 2 diabetes treatment.
    Lebovitz HE
    Endocrinol Nutr; 2009 Dec; 56 Suppl 4():46-9. PubMed ID: 20629232
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.